135 related articles for article (PubMed ID: 33649520)
1. Antihypertensive treatment guided by genetics: PEARL-HT, the randomized proof-of-concept trial comparing rostafuroxin with losartan.
Citterio L; Bianchi G; Scioli GA; Glorioso N; Bigazzi R; Cusi D; Staessen JA; Cavuto S; Ferrandi M; Lanzani C; Li X; Lau LF; Chiang CE; Wang TD; Wang KL; Ferrari P; Manunta P
Pharmacogenomics J; 2021 Jun; 21(3):346-358. PubMed ID: 33649520
[TBL] [Abstract][Full Text] [Related]
2. Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 2: clinical studies.
Lanzani C; Citterio L; Glorioso N; Manunta P; Tripodi G; Salvi E; Carpini SD; Ferrandi M; Messaggio E; Staessen JA; Cusi D; Macciardi F; Argiolas G; Valentini G; Ferrari P; Bianchi G
Sci Transl Med; 2010 Nov; 2(59):59ra87. PubMed ID: 21106941
[TBL] [Abstract][Full Text] [Related]
3. Main results of the ouabain and adducin for Specific Intervention on Sodium in Hypertension Trial (OASIS-HT): a randomized placebo-controlled phase-2 dose-finding study of rostafuroxin.
Staessen JA; Thijs L; Stolarz-Skrzypek K; Bacchieri A; Barton J; Espositi ED; de Leeuw PW; Dłużniewski M; Glorioso N; Januszewicz A; Manunta P; Milyagin V; Nikitin Y; Souček M; Lanzani C; Citterio L; Timio M; Tykarski A; Ferrari P; Valentini G; Kawecka-Jaszcz K; Bianchi G
Trials; 2011 Jan; 12():13. PubMed ID: 21235787
[TBL] [Abstract][Full Text] [Related]
4. Rostafuroxin: an ouabain-inhibitor counteracting specific forms of hypertension.
Ferrari P
Biochim Biophys Acta; 2010 Dec; 1802(12):1254-8. PubMed ID: 20083196
[TBL] [Abstract][Full Text] [Related]
5. Targeting Ouabain- and Adducin-dependent mechanisms of hypertension and cardiovascular remodeling as a novel pharmacological approach.
Ferrari P; Ferrandi M; Valentini G; Manunta P; Bianchi G
Med Hypotheses; 2007; 68(6):1307-14. PubMed ID: 17097240
[TBL] [Abstract][Full Text] [Related]
6. Rostafuroxin: an ouabain antagonist that corrects renal and vascular Na+-K+- ATPase alterations in ouabain and adducin-dependent hypertension.
Ferrari P; Ferrandi M; Valentini G; Bianchi G
Am J Physiol Regul Integr Comp Physiol; 2006 Mar; 290(3):R529-35. PubMed ID: 16467500
[TBL] [Abstract][Full Text] [Related]
7. Rostafuroxin protects from podocyte injury and proteinuria induced by adducin genetic variants and ouabain.
Ferrandi M; Molinari I; Rastaldi MP; Ferrari P; Bianchi G; Manunta P
J Pharmacol Exp Ther; 2014 Nov; 351(2):278-87. PubMed ID: 25187430
[TBL] [Abstract][Full Text] [Related]
8. Adducin- and ouabain-related gene variants predict the antihypertensive activity of rostafuroxin, part 1: experimental studies.
Ferrandi M; Molinari I; Torielli L; Padoani G; Salardi S; Rastaldi MP; Ferrari P; Bianchi G
Sci Transl Med; 2010 Nov; 2(59):59ra86. PubMed ID: 21106940
[TBL] [Abstract][Full Text] [Related]
9. OASIS-HT: design of a pharmacogenomic dose-finding study.
Staessen JA; Kuznetsova T; Acceto R; Bacchieri A; Brand E; Burnier M; Celis H; Citterio L; de Leeuw PW; Filipovský J; Fournier A; Kawecka-Jaszcz K; Manunta P; Nikitin Y; O'Brien ET; Redón J; Thijs L; Ferrari P; Valentini G; Bianchi G
Pharmacogenomics; 2005 Oct; 6(7):755-75. PubMed ID: 16207152
[TBL] [Abstract][Full Text] [Related]
10. Ouabain-dependent signaling in caveolae as a novel therapeutic target for hypertension.
Ferrandi M; Molinari I; Bianchi G; Ferrari P
Cell Mol Biol (Noisy-le-grand); 2006 Dec; 52(8):15-8. PubMed ID: 17535730
[TBL] [Abstract][Full Text] [Related]
11. Ouabain antagonists as antihypertensive agents.
Ferrandi M; Barassi P; Molinari I; Torielli L; Tripodi G; Minotti E; Bianchi G; Ferrari P
Curr Pharm Des; 2005; 11(25):3301-5. PubMed ID: 16250857
[TBL] [Abstract][Full Text] [Related]
12. A new antihypertensive agent that antagonizes the prohypertensive effect of endogenous ouabain and adducin.
Manunta P; Ferrandi M; Messaggio E; Ferrari P
Cardiovasc Hematol Agents Med Chem; 2006 Jan; 4(1):61-6. PubMed ID: 16529550
[TBL] [Abstract][Full Text] [Related]
13. Personalized Therapy of Hypertension: the Past and the Future.
Manunta P; Ferrandi M; Cusi D; Ferrari P; Staessen J; Bianchi G
Curr Hypertens Rep; 2016 Mar; 18(3):24. PubMed ID: 26915067
[TBL] [Abstract][Full Text] [Related]
14. Genetics of primary hypertension: the clinical impact of adducin polymorphisms.
Citterio L; Lanzani C; Manunta P; Bianchi G
Biochim Biophys Acta; 2010 Dec; 1802(12):1285-98. PubMed ID: 20382219
[TBL] [Abstract][Full Text] [Related]
15. Lanosterol Synthase Genetic Variants, Endogenous Ouabain, and Both Acute and Chronic Kidney Injury.
Iatrino R; Lanzani C; Bignami E; Casamassima N; Citterio L; Meroni R; Zagato L; Zangrillo A; Alfieri O; Fontana S; Macrina L; Delli Carpini S; Messaggio E; Brioni E; Dell'Antonio G; Manunta P; Hamlyn JM; Simonini M
Am J Kidney Dis; 2019 Apr; 73(4):504-512. PubMed ID: 30660405
[TBL] [Abstract][Full Text] [Related]
16. PST 2238: A new antihypertensive compound that modulates Na,K-ATPase in genetic hypertension.
Ferrari P; Ferrandi M; Tripodi G; Torielli L; Padoani G; Minotti E; Melloni P; Bianchi G
J Pharmacol Exp Ther; 1999 Mar; 288(3):1074-83. PubMed ID: 10027844
[TBL] [Abstract][Full Text] [Related]
17. Blood pressure reduction and antihypertensive medication use in the losartan intervention for endpoint reduction in hypertension (LIFE) study in patients with hypertension and left ventricular hypertrophy.
Devereux RB; de Faire U; Fyhrquist F; Harris KE; Ibsen H; Kjeldsen SE; Lederballe-Pedersen O; Lindholm LH; Nieminen MS; Omvik P; Oparil S; Wedel H; Hille DA; Dahlöf B
Curr Med Res Opin; 2007 Feb; 23(2):259-70. PubMed ID: 17288679
[TBL] [Abstract][Full Text] [Related]
18. Ouabain Contributes to Kidney Damage in a Rat Model of Renal Ischemia-Reperfusion Injury.
Villa L; Buono R; Ferrandi M; Molinari I; Benigni F; Bettiga A; Colciago G; Ikehata M; Messaggio E; Rastaldi MP; Montorsi F; Salonia A; Manunta P
Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27754425
[TBL] [Abstract][Full Text] [Related]
19. Ambulatory monitoring of systolic hypertension in the elderly: Eprosartan/hydrochlorothiazide compared with losartan/hydrochlorothiazide (INSIST trial).
Ambrosioni E; Bombelli M; Cerasola G; Cipollone F; Ferri C; Grazioli I; Leprotti C; Mancia G; Melzi G; Mugellini A; Mulè G; Palasciano G; Salvetti A; Trimarco B
Adv Ther; 2010 Jun; 27(6):365-80. PubMed ID: 20556561
[TBL] [Abstract][Full Text] [Related]
20. Rostafuroxin ameliorates endothelial dysfunction and oxidative stress in resistance arteries from deoxycorticosterone acetate-salt hypertensive rats: the role of Na+K+-ATPase/ cSRC pathway.
Wenceslau CF; Rossoni LV
J Hypertens; 2014 Mar; 32(3):542-54. PubMed ID: 24309491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
